Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
ZC

Zhijian James Chen

Scientific advisor and co-founder, Drug Farm

Appears in 1 story

Stories

Drug Farm advances first potential therapy for rare ROSAH syndrome

New Capabilities

Advising the ALPK1 programs

A few dozen families worldwide carry a gene mutation that slowly steals their sight and floods their bodies with inflammation. There is no approved drug that treats the cause. On July 13, 2026, Drug Farm said it raised $55 million to move its candidate for that disease, ROSAH syndrome, toward a Phase 3 trial.

Updated Yesterday